Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon [beta]

Authors :: Bielekova, Bibiana
Richert, Nancy
Howard, Thomas
Blevins, Gregg
Markovic-Plese, Silva
McCartin, Jennifer
Wurfel, Jens
Ohayon, Joan
Waldmann, Thomas A.
McFarland, Henry F.
Martin, Roland
Source :: Proceedings of the National Academy of Sciences of the United States. June 8, 2004, Vol. 101 Issue 23, p8705, 4 p.
Publication Year :: 2004
Abstract: Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-[beta] therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.

Subjects :: Multiple sclerosis -- Research
Multiple sclerosis -- Care and treatment
Science and technology
National Academy of Sciences -- Research

Language :: English
ISSN :: 00278424
Volume :: 101
Issue :: 23
Database :: Gale General OneFile
Journal :: Proceedings of the National Academy of Sciences of the United States
Publication Type :: Academic Journal
Accession number :: edsgcl.119782225

Tools